問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Nuclear Medicine

Taoyuan Chang Gung Memorial Hospital of The C.G.M.F. (在職)

Division of Nuclear Medicine

更新時間：2023-09-24

林昆儒Lin, Kun-Ju
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

26Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林昆儒

List

70Cases

2020-08-01 - 2022-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-08-01 - 2024-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2017-08-01 - 2025-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-08-01 - 2020-11-04

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2019-01-01 - 2020-12-31

Phase II

Topography Staging and Dual Phase Image Quantification of Tau PET in Cognitive Impairment Subjects

  • Condition/Disease

    Alzheimer's disease

  • Test Drug

    18F-PMPBB3

Participate Sites
2Sites

Recruiting2Sites

2019-08-01 - 2021-07-31

Phase II

Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination

  • Condition/Disease

    investigate the deposition patterns of tau protein with 18F-PM-PBB3 and amyloid protein with 18F-flobetapir in patients with amnestic mild cognitive impairment due to AD

  • Test Drug

    18F-AV-45 for Injection, and 18F-PM-PBB3 for Injection

Participate Sites
1Sites

Recruiting1Sites

2019-08-01 - 2022-07-31

Phase II

A noval tau tracer ([ 18F]PM-PBB3) in young onset dementia: clinical and neuroimaging study

  • Condition/Disease

    *PRESENILE DEMENTIA;SENILE DEMENTIA, UNCOMPLICATED;DEMENTIA IN CONDITIONS CLASSIFIED ELSEWHERE;AMNESTIC  SYNDROME

  • Test Drug

    (1)[F18] AV-45 (2) [F-18] PM-PBB3

Participate Sites
3Sites

Recruiting3Sites

2018-09-21 - 2028-11-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-08-01 - 2024-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-08-01 - 2022-10-31

Phase II

To study the pathophysiological features of multiple sclerosis: combined multi-modalities of amyloid and tau images associated with serum neurofilament light chain levels

  • Condition/Disease

    *PRESENILE DEMENTIA;SENILE DEMENTIA, UNCOMPLICATED;DEMENTIA IN CONDITIONS CLASSIFIED ELSEWHERE;AMNESTIC  SYNDROME

  • Test Drug

    (1)[F18] AV-45 (2) [F-18] PM-PBB3

Participate Sites
1Sites

Recruiting1Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB